Floatz logo

ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)

Stage IIIB Bladder Cancer AJCC v8

Fred Hutchinson Cancer Centerantibody_drug_conjugatePhase 2Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
95/ 100

Competitive context

22 Active assets in the Stage IIIB Bladder Cancer AJCC v8 cohort.

Asset / SponsorPhaseRating
Atezolizumab
National Cancer Institute (NCI)
Phase 2BB
Carboplatin
Iambic Therapeutics, Inc
Phase 2BB
Pembrolizumab
Fred Hutchinson Cancer Center
Phase 2BB
TRASTUZUMAB
Iambic Therapeutics, Inc
Phase 2BB
Nivolumab
M.D. Anderson Cancer Center
Phase 2B

View all 45 →

Same molecule, other indications

ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4) is also rated in:

urothelial carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
urinary bladder neoplasmDormant
BB
Indicative ·
68 / 100
View asset →
ureter neoplasmDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →